Application of astilbin to preparation of medicine for treating diabetic gangrene

A technology of diabetic gangrene and astilbin, which is applied in the application field of astilbin in the preparation of drugs for treating diabetic gangrene, can solve the problems of large side effects and low compliance of diabetic gangrene, and achieve improved compliance, low side effects, slow down The effect of development

Inactive Publication Date: 2018-04-13
珠海霍普金斯医药研究院股份有限公司 +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to provide the application of astilbin in the preparation of drugs for the treatment of diabet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of astilbin to preparation of medicine for treating diabetic gangrene
  • Application of astilbin to preparation of medicine for treating diabetic gangrene
  • Application of astilbin to preparation of medicine for treating diabetic gangrene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Astilbin inhibits the secretion of inflammatory factors in macrophages in vitro

[0019] The mouse peritoneal macrophage cell line Raw 264.7 was cultured in a cell culture incubator with DMEM medium containing 10% fetal bovine serum. After the cells grow well, digest the cells, and dilute 100 μL of the cell suspension according to 1×10 6 / L concentration was inoculated into 96-well plates, and then divided into blank control group, model group, and dexamethasone group (10 -7 mol / L) and astilbin high concentration group (10 -5 mol / L), medium concentration group (10 -6 mol / L), low concentration group (10 -7 mol / L), and 5 wells were made for each concentration group. Except for the blank group which was added with 100 μL of PBS, the rest of the groups were stimulated with 5 mg / L lipopolysaccharide LPS. After incubation for 48 hours, the cell supernatant was collected and centrifuged to detect the contents of TNF-α and IL-6 in the supernatant according to the instructi...

Embodiment 2

[0026] Experiment of astilbin reducing wound area in diabetic gangrene mice

[0027] 50 mice were randomly divided into 5 groups, 10 in each group, respectively high-dose metformin group (200mg / kg), low-dose metformin group (50mg / kg), high-dose astilbinin group (200mg / kg), Astilbin low dose group (50mg / kg) and model group. The mice in each group were intraperitoneally injected with streptozotocin (STZ) 35 mg / kg every day for 4 consecutive days. After 4 weeks, a full-thickness wound (2mm×4mm) was prepared on the skin of the back of the lower limb and near the leg of the mouse after anesthesia to establish a mouse model of diabetic gangrene. After the operation, the rats were given intragastric administration once a day, and the model group was given the same volume of drinking water by intragastric administration. At the same time, the wound healing of the mice in each group was observed daily, and the wounds were photographed on the 15th day, and the wound area was measured ...

Embodiment 3

[0033] Wang Moumou, male, 51 years old, has a history of diabetes for 10 years. When the patient came to the doctor, the skin color of his feet was dark, the dorsum of his feet was red and swollen, the little toes of his feet were purple and black with ulceration, and the pulse of the dorsal artery of both feet was weak. Astilbin 500mg was taken twice, 4 weeks as a course of treatment. After taking the medicine, the symptoms of diabetic foot gangrene were significantly improved, and he basically recovered after continuing to take the medicine for two months, and there was no recurrence in the follow-up for two years.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to novel application of astilbin, in particular to application of astilbin to the preparation of medicine for treating diabetic gangrene. The astilbin can reduce a side effect during the treatment of diabetic gangrene, cannot damage organs of human body, such as liver, kidney, heart and brain, and slows down the development of complication; the astilbin can improve symptoms of diabetic gangrene, and can greatly reduce ulearation, necrosis, dryness, blackening, purulency and infection of four limbs; the astilbin can improve the treatment compliance because the astilbin obtains certain curative effect in clinic treatment and meanwhile keeps very low side reaction.

Description

technical field [0001] The present invention relates to the new application of astilbin, in particular to the application of astilbin in the preparation of medicine for treating diabetic gangrene. Background technique [0002] Diabetic gangrene mostly occurs in middle-aged and elderly people; more men than women, the ratio of men to women is 3:2; the average course of diabetes is about 10 years, gangrene is more common in the lower limbs, accounting for 92.5%, rare in the upper limbs, accounting for 7.5%; unilateral disease It accounts for about 80%, and bilateral simultaneous disease accounts for about 20%; simultaneous gangrene of toes and soles is more common, accounting for 77.5%; simultaneous gangrene of toes and lower legs accounts for 5%, and only calf gangrene accounts for 5%; toe or finger gangrene Incidence accounted for 12.5%. Diabetic gangrene is more common in obese or adult diabetic patients with a long course of disease, with an average of about 10 years. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P3/10A61P17/02
CPCA61K31/7048
Inventor 曹文强刘天赫赵柏松
Owner 珠海霍普金斯医药研究院股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap